Down-regulation of prostasin serine protease: A potential invasion suppressor in prostate cancer

被引:66
作者
Chen, LM
Hodge, GB
Guarda, LA
Welch, JL
Greenberg, NM
Chai, KX
机构
[1] Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32816 USA
[2] Florida Hosp Med Ctr, Walt Disney Mem Canc Inst, Orlando, FL 32803 USA
[3] Florida Hosp Med Ctr, Dept Pathol, Orlando, FL 32803 USA
[4] MD Anderson Canc Ctr, Orlando, FL USA
[5] Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA
关键词
cell line; gene expression; immunohistochemistry; prostatectomy; transfection;
D O I
10.1002/pros.1085
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. Prostasin is a serine protease predominantly expressed in normal prostate epithelial cells. The biological function of prostasin has not been determined. METHODS. Western blot and RT-PCR analyses were used to examine the expression of prostasin in prostate cancer cell lines. Immunohistochemistry was used to evaluate prostasin protein expression in human prostate cancer. An in vitro Matrigel invasion assay was used to test the invasiveness Of prostate cancer cell lines forced to express recombinant prostasin. RESULTS. Both prostasin protein and mRNA were found to be expressed in normal human prostate epithelial cells and a non-invasive human prostate cancer cell line, the LNCaP, but neither was found in invasive human prostate cancer cell lines DU-145 and PC-3. Prostasin mRNA expression was absent in invasive prostate cancer cell lines of a transgenic mouse model. Immunohistochemistry analysis showed that prostasin protein expression is downregulated in high-grade prostate cancer. Transfection of DU-145 and PC-3 cells with a full-length human prostasin cDNA restored prostasin expression and reduced the in vitro invasiveness by 68 and 42%, respectively. CONCLUSIONS. Our data indicate that prostasin may be implicated in normal prostate biology and is able to suppress prostate cancer invasion in vitro. (C) 2001 Wiley-Liss, Inc.
引用
收藏
页码:93 / 103
页数:11
相关论文
共 18 条
[1]  
[Anonymous], GENETIC BASIS HUMAN
[2]  
BOUCAUT K, 2000, CANC GEN TUM SUPPR G
[3]  
Foster BA, 1997, CANCER RES, V57, P3325
[4]  
GLEASON DONALD F., 1966, CANCER CHEMO THERAP REP, V50, P125
[5]  
Goyal J, 1998, CANCER RES, V58, P4782
[6]   PROSTATE-CANCER IN A TRANSGENIC MOUSE [J].
GREENBERG, NM ;
DEMAYO, F ;
FINEGOLD, MJ ;
MEDINA, D ;
TILLEY, WD ;
ASPINALL, JO ;
CUNHA, GR ;
DONJACOUR, AA ;
MATUSIK, RJ ;
ROSEN, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (08) :3439-3443
[7]   Cancer statistics, 2000 [J].
Greenlee, RT ;
Murray, T ;
Bolden, S ;
Wingo, PA .
CA-A CANCER JOURNAL FOR CLINICIANS, 2000, 50 (01) :7-33
[8]  
Hooper JD, 1999, CANCER RES, V59, P3199
[9]   DIFFERENTIAL-EFFECTS OF PEPTIDE-HORMONES BOMBESIN, VASOACTIVE INTESTINAL POLYPEPTIDE AND SOMATOSTATIN ANALOG RC-160 ON THE INVASIVE CAPACITY OF HUMAN PROSTATIC-CARCINOMA CELLS [J].
HOOSEIN, NM ;
LOGOTHETIS, CJ ;
CHUNG, LWK .
JOURNAL OF UROLOGY, 1993, 149 (05) :1209-1213
[10]  
Kassis J, 1999, CLIN CANCER RES, V5, P2251